Amyloid Myopathy With and Without Systemic Amyloidosis (S54.006)
Conclusions:About 1/3 of amyloid myopathy patients have amyloid deposits exclusively in skeletal muscle. Molecular defects remain unknown in 45% of patients with isolated amyloid myopathy. Anoctaminopathy-5 accounts for 80% of genetically-diagnosed isolated amyloid myopathy. Clinical, laboratory and pathological features may help differentiate between amyloid myopathy with and without systemic amyloidosis.Disclosure: Dr. Liewluck has nothing to disclose. Dr. Milone has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Liewluck, T., Milone, M. Tags: Motor Neuron Disease and Myopathies Source Type: research
More News: Amyloidosis | Brain | Cardiology | Cardiomyopathy | Genetics | Heart | Laboratory Medicine | Motor Neurone Disease | Neurology | Peripheral Neuropathy